Category: Federal Forum Posters
Purpose: This study aims to compare the international normalized ratio (INR) with the chromogenic factor X (CFX) assay in warfarin monitoring to assess therapeutic anticoagulation in patients with antiphospholipid syndrome (APS), specifically, positive for the lupus anticoagulant (LA) antibody. This study will provide preliminary data on whether CFX monitoring is necessary in patients with potentially inaccurate INR during warfarin therapy. Subsequently, this study could lead to warfarin protocol changes at Veterans Affairs Eastern Colorado Health Care System if the relationship of CFX with the INR needs to be quantitated to have protocols that are equivalent with CFX as a monitoring parameter.
Methods: This study will be submitted to the Institutional Review Board for approval. This will be a prospective cohort study with a study duration from December 2018 - May 2019. Subjects meeting the inclusion criteria (age greater than 18 years of age but less than 90 years old, clinical diagnosis of antiphospholipid syndrome (lupus anticoagulant, anticardiolipin or beta-2 glycoprotein I antibodies) in which patient is receiving warfarin therapy for secondary prevention of thrombosis) will be recruited from the Veterans Affairs Eastern Colorado Health Care System (VA ECHCS) Anticoagulant Clinic. The biological samples collected for this study will include blood by venipuncture at the VA ECHCS's laboratory. Subjects will get blood drawn for tests including the prothrombin time (PT)/INR (usual standard of care), lupus anticoagulant assay, and chromogenic X assay. Data will be analyzed both with descriptive statistics and correlation will be used to compare INR and CFX levels.
Results: Not applicable
Conclusion: Not applicable
Hlee Lor– Student, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO